EUVIMEDEUVIMED entdecken
Crossref

Investigation of clinicopathological and prognostic association of TERT promoter mutation in non-small cell lung cancer in a Turkish population

Onur Dülger, Ilhan Yaylim, Ismail Yilmaz, Fatma Sen, Büge Öz

Polish Journal of Pathology · 2025

DOI: 10.5114/pjp.2025.149380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Polish Journal of Pathology, 2025. Verfasst von Onur Dülger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Telomerase, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Promoter Regions, Genetic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is characterized by a complex and heterogeneous molecular basis. Telomerase reverse transcriptase ( TERT ) gene promoter mutations have been implicated in various cancer types. We aimed to investigate the status of TERT promoter region mutations in NSCLCs and determine associations of clinicopathological connections, driver mutations, programmed death-ligand 1 (PD-L1) expression, and overall survival (OS) in the Turkish population. The study included 186 patients diagnosed with NSCLC at a tertiary care center pathology department between 2017 and 2022. TERT promoter mutations were present in 2.7% and associated with old age ( p = 0.015). The levels of PD-L1 expression were higher in TERT mutants ( p = 0.016). TERT mutants had shorter median OS than wild types ( p = 0.006) and TERT mutation was an independent risk factor ( p = 0.004). TERT and EGFR mutations may co-occur and be associated with shorter median OS in patients who continue to receive EGFR treatment ( p < 0.001). TERT promoter mutations were associated with high PD-L1 expression and adverse prognosis in NSCLC. In addition, they may play a major role in patients' poor clinical outcomes during EGFR therapy. In conclusion, TERT may be a significant parameter for future follow-up and treatment selection of NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelomeraseCarcinoma, Non-Small-Cell LungLung NeoplasmsPromoter Regions, GeneticMutationBiomarkers, TumorHumansMaleFemaleTurkeyMiddle AgedAgedPrognosisAdultAged, 80 and overB7-H1 Antigen

Stichwörter der Autor:innen

TERT mutationnon-small cell lung cancerprognosisclinicopathological features

Substanzen

TelomeraseTERT protein, humanBiomarkers, TumorB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Pathology, Abdulhamid Han Research and Training Hospital, University of Health Sciences, Istanbul, Turkey.
  • Department of Medical Oncology, Avrasya Hospital, Istanbul, Turkey.
  • Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Zitieren

APA

Dülger, O., Yaylim, I., Yilmaz, I., Sen, F., & Öz, B. (2025). Investigation of clinicopathological and prognostic association of TERT promoter mutation in non-small cell lung cancer in a Turkish population. Polish Journal of Pathology. https://doi.org/10.5114/pjp.2025.149380

Vancouver

Dülger O, Yaylim I, Yilmaz I, Sen F, Öz B. Investigation of clinicopathological and prognostic association of TERT promoter mutation in non-small cell lung cancer in a Turkish population. Polish Journal of Pathology. 2025. doi:10.5114/pjp.2025.149380

BibTeX
@article{Dlger2025,
  author = {Dülger, Onur and Yaylim, Ilhan and Yilmaz, Ismail and Sen, Fatma and Öz, Büge},
  title = {Investigation of clinicopathological and prognostic association of TERT promoter mutation in non-small cell lung cancer in a Turkish population},
  journal = {Polish Journal of Pathology},
  year = {2025},
  doi = {10.5114/pjp.2025.149380}
}
Kostenlos starten →